Nishant Gupta, MD
Interventional Cardiology · Phoenix, AZNPI 1366609620
Payments from drug & device makers
What this record shows
This record is dominated by speaking fees: $121,124 of the $144,930 with a category attached, or 83.6%. Medtronic accounts for 91.0% of it on its own, with 38 other manufacturers making up the rest. Reporting peaked in 2020 at $42,763 and has fallen 66.1% since, to $14,491 in 2025. Among interventional cardiology clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 497 payments — averaging $291.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Medtronic$132K
- Abbott$4K
- Abiomed$2K
- Biosense Webster, Inc.$1K
- Boston Scientific$1K
- Edwards Lifesciences$729
- plus $4K from 33 others
Across 2 payments — averaging $25,498 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Pfizer$30K
- Novartis$21K
What the payments were for
- Speaking & faculty fees$121,12484%
- Travel & lodging$8,4546%
- Food & beverage$15,35211%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- CoreValve Evolut$95,634
- COREVALVE EVOLUT R$32,865
- TRICLIP$1,373
- ClosureFast$985
- Impella$909
- Carto 3 System$478
- Quadra Allure MP RF CRT Pacemkr$253
- GENERAL - THERAPIES$248
- Confirm Rx$213
- PORTICO$212
- MitraClip System$175
- MitraClip$163
- EPI-SENSE GUIDED COAGULATION SYSTEM WITH VISITRAX$154
- Micra$140
- Carto 3$136
- OCTARAY MAPPING CATHETER$136
- NUVISION ICE CATHETER$136
- Carto Smarttouch$124
- Xience V coronary stent system$123
- Quadra Assura CRT Defibrillator$120
How this compares
$144,930 in reported general payments places this provider in the 95th percentile of 223 interventional cardiology providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| EliquisApixaban | 459 | $497,909 |
| JardianceEmpagliflozin | 116 | $100,254 |
| Repatha SureclickEvolocumab | 132 | $83,608 |
| EntrestoSacubitril/Valsartan | 67 | $78,314 |
| XareltoRivaroxaban | 64 | $72,548 |
| FarxigaDapagliflozin Propanediol | 58 | $41,575 |
| Repatha SyringeEvolocumab | 39 | $36,309 |
| BrilintaTicagrelor | 34 | $25,431 |
| Praluent PenAlirocumab | 32 | $22,507 |
| VascepaIcosapent Ethyl | 27 | $17,140 |
| Metoprolol Succinate | 799 | $10,922 |
| Ranolazine ErRanolazine | 62 | $9,002 |
| Atorvastatin Calcium | 660 | $5,758 |
| Flecainide Acetate | 78 | $5,263 |
| ClopidogrelClopidogrel Bisulfate | 432 | $4,734 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| PfizerEliquis | $126 | $497,909459 claims |
| Boehringer IngelheimJardiance | $91 | $100,254116 claims |
| NovartisEntresto | $514 | $78,31467 claims |
| Johnson & JohnsonXarelto | $101 | $72,54864 claims |
| AstraZenecaFarxiga, Brilinta | $195 | $67,00692 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 223 interventional cardiology providers in Arizona.
Other interventional cardiology in Phoenix
- Paul SorajjaPhoenix$1.1M
- Timothy ByrnePhoenix$614K
- Haidar YassinPhoenix$434K
- Akil LoliPhoenix$160K
- Richard HeuserPhoenix$68K
- Nezar FallujiPhoenix$50K
- Ahmad JabriPhoenix$39K
- Edward EvansPhoenix$36K
- Basil Al KhatibPhoenix$33K
- Sourabh AggarwalPhoenix$29K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.